Form 4: Axsome Director Sells Shares After Option Exercise
Insider Transaction Report
Axsome Therapeutics Director Mark E. Saad exercised stock options and subsequently sold the acquired common stock, as disclosed in a recent Form 4 filing.
Summary
- Director Mark E. Saad exercised stock options for a total of 37,577 shares of Axsome Therapeutics common stock on December 31, 2025.
- The exercised options included 6,231 shares at an exercise price of $8.02 and 31,346 shares at an exercise price of $4.95.
- Immediately following the exercise, Saad sold all 37,577 shares acquired from the option exercises at a weighted average sale price of $165.18 per share.
- These transactions were conducted pursuant to a pre-approved Rule 10b5-1 plan.
- After these transactions, Saad directly holds 10,002 shares and indirectly holds 300 shares through UTMA accounts.
Sentiment
Score: 5
Explanation: The filing reports a director's pre-planned exercise of stock options and subsequent sale of shares, which is a personal financial event rather than an indicator of company performance or strategic direction. The use of a 10b5-1 plan mitigates concerns about opportunistic selling.
Positives
- Director Mark E. Saad realized significant gains by exercising stock options at prices of $8.02 and $4.95 and selling the shares at a weighted average price of $165.18.
- The transactions were executed under a Rule 10b5-1 plan, indicating a pre-scheduled and non-discretionary sale, which can mitigate concerns about opportunistic insider selling.
Negatives
- A director selling a significant number of shares (37,577) could be interpreted by some investors as a potential negative signal, even if pre-planned.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may interpret the director's sale of a significant number of shares as a potential negative signal, although the pre-planned nature via a Rule 10b5-1 plan suggests it is not based on new, undisclosed information.
Key Dates
| Date | Description |
|---|---|
| 05/27/2017 | Date exercisable for 6,231 stock options. |
| 03/15/2018 | Date exercisable for 31,346 stock options. |
| 12/31/2025 | Date of stock option exercise and subsequent sale of common stock. |
| 01/02/2026 | Signature date of the reporting person's attorney-in-fact. |
| 05/27/2026 | Expiration date for 6,231 stock options. |
| 03/15/2027 | Expiration date for 31,346 stock options. |
Keywords
Axsome Therapeutics, AXSM, Insider Trading, Form 4, Stock Options, Director Sale, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.